Biointegrator LLC Report issue

Government Phase 1

Organization Overview

First Clinical Trial
2013
NCT03057418
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 1 Trials (2)

bi-con-02 (1 trial)

rituximab (rituxan) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Breast Neoplasms (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Follicular (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 2